` SLRN (ACELYRIN Inc) vs S&P 500 Comparison - Alpha Spread

SLRN
vs
S&P 500

Over the past 12 months, SLRN has underperformed S&P 500, delivering a return of -48% compared to the S&P 500's 12% growth.

Stocks Performance
SLRN vs S&P 500

Loading
SLRN
S&P 500
Add Stock

Performance Gap
SLRN vs S&P 500

Loading
SLRN
S&P 500
Difference

Performance By Year
SLRN vs S&P 500

Loading
SLRN
S&P 500
Add Stock

Competitors Performance
ACELYRIN Inc vs Peers

S&P 500
SLRN
ABBV
AMGN
GILD
VRTX
Add Stock

ACELYRIN Inc
Glance View

Market Cap
226m USD
Industry
Biotechnology

ACELYRIN Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Agoura Hills, California and currently employs 51 full-time employees. The company went IPO on 2023-05-05. ACELYRIN, INC. is a late-stage clinical biopharmaceutical company. The firm is focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. Its initial focus is on the treatment of diseases with pathology related to excess activation of the immune system. The Company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit anti-interleukin (IL)-17A with high potency through tight binding affinity and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody. The company is also advancing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R). Lonigutamab has shown high potency against IGF-1R in both binding and functional laboratory assays. In addition, the Company is developing SLRN-517, which is a fully human IgG1 monoclonal antibody targeting c-KIT.

SLRN Intrinsic Value
4.44 USD
Undervaluation 49%
Intrinsic Value
Price
A
Back to Top